BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34532996)

  • 1. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease.
    Luo F; Oldoni F; Das A
    Hepatol Commun; 2022 Mar; 6(3):448-460. PubMed ID: 34532996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
    Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
    Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research progress on the relationship between TM6SF2 rs58542926 polymorphism and non-alcoholic fatty liver disease.
    Xue WY; Zhang L; Liu CM; Gao Y; Li SJ; Huai ZY; Dai J; Wang YY
    Expert Rev Gastroenterol Hepatol; 2022 Feb; 16(2):97-107. PubMed ID: 35057689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
    Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
    JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism and therapeutic strategy of hepatic
    Li ZY; Wu G; Qiu C; Zhou ZJ; Wang YP; Song GH; Xiao C; Zhang X; Deng GL; Wang RT; Yang YL; Wang XL
    World J Gastroenterol; 2022 Jul; 28(25):2937-2954. PubMed ID: 35978872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
    Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
    PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Genetics of Clinical Liver Diseases: Insight into the
    Zhang X; Liu S; Dong Q; Xin Y; Xuan S
    J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
    J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease.
    Chen LZ; Xia HH; Xin YN; Lin ZH; Xuan SY
    J Clin Transl Hepatol; 2015 Dec; 3(4):265-70. PubMed ID: 26807382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the association between MBOAT7 rs641738, TM6SF2 rs58542926 and nonalcoholic fatty liver disease susceptibility.
    Xia Y; Huang CX; Li GY; Chen KH; Han L; Tang L; Luo HQ; Bao MH
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):533-541. PubMed ID: 30824369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
    Pirola CJ; Sookoian S
    Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
    Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
    Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of single-nucleotide polymorphism in theTM6SF2 rs58542926].
    Li Y; Sun X; Zhan SH; Gao YQ; Xin YN; Xuan SY
    Zhonghua Gan Zang Bing Za Zhi; 2019 Mar; 27(3):223-226. PubMed ID: 30929342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population.
    Li Y; Liu S; Gao Y; Ma H; Zhan S; Yang Y; Xin Y; Xuan S
    BMC Biochem; 2019 Feb; 20(1):3. PubMed ID: 30727943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perturbation of
    Pant A; Chen Y; Kuppa A; Du X; Halligan BD; Speliotes EK
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
    Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
    Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of TM6SF2 rs58542926 polymorphism on hepatocellular lipids and insulin resistance in early type 2 diabetes.
    Bódis K; Bombrich M; Schön M; Knebel B; Zaharia OP; Bönhof G; Karusheva Y; Strassburger K; Kupriyanova Y; Kotzka J; Guthoff R; Schrauwen-Hinderling V; Al-Hasani H; Burkart V; Szendroedi J; Wagner R; Markgraf DF; Roden M;
    Nutr Metab Cardiovasc Dis; 2023 Sep; 33(9):1785-1796. PubMed ID: 37495452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.